➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
Boehringer Ingelheim
Express Scripts
Moodys

Last Updated: May 10, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LONSURF

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lonsurf

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01896856 Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Recruiting Sidney Kimmel Comprehensive Cancer Center Phase 1/Phase 2 2013-09-01 This is a phase I/randomized phase II study of the combination of SGI-110 and previously treated metastatic colorectal cancer patients. This study will be conducted in two components. First, patients will be enrolled in a phase I study of SGI-110 combined with irinotecan in a standard 3+3 design. After the maximum tolerated dose (MTD) is determined, patients will subsequently be enrolled in a 2:1 randomized phase II study of SGI-110 and irinotecan versus the standard of care regorafenib or TAS-102.
NCT02602327 Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases Recruiting University of California, San Francisco Phase 1 2016-10-01 This is a phase I dose escalation study (3+3 design) with a dose expansion arm (12 patients) designed to evaluate safety of the combination of Tas-102 and radioembolization using Yttrium-90 (90Y) resin microspheres for patients with chemotherapy-refractory liver-dominant chemotherapy-refractory metastatic colorectal cancer (mCRC).
NCT02654639 Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer Recruiting Georgetown University Phase 2 2016-02-01 Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
NCT02920476 TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma Not yet recruiting Taiho Oncology, Inc. Phase 2 2017-02-01 This is a non-randomized, open label, sequentially enrolling phase II study with a Simon two-step enrollment design to evaluate the activity of TAS-102 in previously treated unresectable or metastatic squamous non-small cell cancer after progression through or intolerance to prior systemic therapy. The trial therapy of TAS-102 is to be administered orally at 35 mg/m2 each dose twice daily. The primary objective of the trial is to determine the progression-free survival, in months, of subjects receiving TAS 102 for the treatment of unresectable or metastatic recurrent squamous non-small cell lung cancers.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lonsurf

Condition Name

Condition Name for Lonsurf
Intervention Trials
Stage IVB Colorectal Cancer AJCC v8 5
Stage IVC Colorectal Cancer AJCC v8 5
Stage IVA Colorectal Cancer AJCC v8 5
Metastatic Colorectal Cancer 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lonsurf
Intervention Trials
Colorectal Neoplasms 21
Adenocarcinoma 13
Carcinoma 7
Colonic Neoplasms 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lonsurf

Trials by Country

Trials by Country for Lonsurf
Location Trials
United States 48
Germany 2
Singapore 2
France 2
Czechia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lonsurf
Location Trials
Florida 6
California 6
Arizona 5
Texas 4
Minnesota 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lonsurf

Clinical Trial Phase

Clinical Trial Phase for Lonsurf
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 1
Phase 2 23
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lonsurf
Clinical Trial Phase Trials
Not yet recruiting 29
Recruiting 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lonsurf

Sponsor Name

Sponsor Name for Lonsurf
Sponsor Trials
National Cancer Institute (NCI) 11
Taiho Oncology, Inc. 7
Academic and Community Cancer Research United 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lonsurf
Sponsor Trials
Other 44
Industry 17
NIH 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Colorcon
Boehringer Ingelheim
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.